GNBT - Generex Biotechnology Corporation

Other OTC - Other OTC Delayed Price. Currency in USD

Generex Biotechnology Corporation

10102 USA Today Way
Suite 200
Miramar, FL 33025
United States

IndustryDrug Delivery
Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Mr. Joseph MoscatoCEO, Pres & ChairmanN/AN/A1964
Mr. Mark CorraoCFO & TreasurerN/AN/A1959
Mr. Andrew RoChief Investment Officer, Sr. VP of Investments & DirectorN/AN/A1971
Mr. Mark A. Fletcher Esq.Exec. VP, Gen. Counsel & Sec.71.46kN/A1965
Mr. Richard D. PurcellSr. VP of Research & Drug Devel.N/AN/A1961
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Generex Biotechnology Corporation, through its subsidiary, Hema Diagnostic Systems, LLC, focuses on the development, manufacture, and distribution of in-vitro medical diagnostics for infectious diseases in Canada and the United States. The company offers Rapid Diagnostic Tests for human immunodeficiency virus?½ w/p24Ab, tuberculosis-XT, malaria, hepatitis, syphilis, typhoid, dengue, and other infectious diseases. Generex Biotechnology Corporation was founded in 1983 and is based in Miramar, Florida.

Corporate Governance

Generex Biotechnology Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.